* PHENOPRO *
2007 - Alsace
Illkirch
(near Strasbourg)
www.phenopro.com Contract, Services
(also, Contract, Research)
Key words: Translational medicine, Mouse phenotyping, Targets
Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs
Clients: Research labs
contact@phenopro.com
Age: 4 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Schaeffer (Catherine) [born 1962]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Bocquel (François) [M.D., I.A.E., ex-Erudia, UCB Pharma, Parke Davis, Pfizer
Financers (Hist.): privately owned
Communication: no legal accounting information available since inception | Turnover (M€) : none
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Studies
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2008 .08 | Partnering marketing agreement with Oncodesign, OncOptima, a new service offer for the characterization and validation of Genetically Engineered Mouse Model in cancer targeted therapies | MKTG | [0 year] |
| 2007 .09 | Company founded by Nicolas Carboni (chairman, plus Managing Director of the Cluster Alsace-Biovalley, up to 2011), Catherine Schaeffer, and others, as a spin-off from MCI (Mouse Clinical Institute) | ORGF | [0 year] | Actualisation / Updating: 23-Sep-2011 |
|
